Cardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancyShow others and affiliations
2021 (English)In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 125, no 10, p. 1450-1458Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: To assess the risk of cardiovascular mortality among cancer survivors who developed breast cancer as a second malignancy (BCa-2) compared with patients with first primary breast cancer (BCa-1) and the general population.
METHODS: Using the Surveillance, Epidemiology, and End Results database, we conducted a population-based cohort study including 1,024,047 BCa-1 and 41,744 BCa-2 patients diagnosed from the age 30 between 1975 and 2016, and the corresponding US female population (994,415,911 person-years; 5,403,551 cardiovascular deaths). Compared with the general population and BCa-1 patients, we calculated incidence rate ratios (IRRs) of cardiovascular deaths among BCa-2 patients using Poisson regression. To adjust for unmeasured confounders, we performed a nested, case-crossover analysis among BCa-2 patients who died from cardiovascular disease.
RESULTS: Although BCa-2 patients had a mildly increased risk of cardiovascular mortality compared with the population (IRR 1.08) and BCa-1 patients (IRR 1.15), the association was pronounced among individuals aged 30-49 years (BCa-2 vs. population: IRR 6.61; BCa-2 vs. BCa-1: IRR 3.03). The risk elevation was greatest within the first month after diagnosis, compared with the population, but comparable with BCa-1 patients. The case-crossover analysis confirmed these results.
CONCLUSION: Our findings suggest that patients with BCa-2 are at increased risk of cardiovascular mortality.
Place, publisher, year, edition, pages
Nature Publishing Group, 2021. Vol. 125, no 10, p. 1450-1458
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-94647DOI: 10.1038/s41416-021-01549-wISI: 000700976500001PubMedID: 34580431Scopus ID: 2-s2.0-85115783337OAI: oai:DiVA.org:oru-94647DiVA, id: diva2:1598516
Funder
Swedish Research Council, 201800648European Commission
Note
Funding agencies:
National Natural Science Foundation of China (NSFC) 81872307
Full-time Postdoc Research and Development Foundation of West China Hospital 2019HXBH098
2021-09-292021-09-292021-12-01Bibliographically approved